← All organizations
Highest phase reached
Phase 3
First clinical trial
Sep 1, 2006First marketed drug
Sep 8, 2023First NDA
Sep 8, 2023Last known activity
Dec 31, 2024
Timeline
2000s
- Jun 1, 2003
BioLineRx, Ltd.— Founded
2010s
- Aug 5, 2011
Agalimmune Ltd.— Acquired
2020s
- Sep 8, 2023
Motixafortide— Marketing Organization
- Sep 8, 2023
Motixafortide— NDA Organization
Drugs by trial phase (28 distinct, 26 trials)
Phase 3 (4 own, 0 via acquisition)
Phase 2 (18 own, 1 via acquisition)
Phase 1 (4 own, 0 via acquisition)
Other trials (1 own, 0 via acquisition)
Indications
Studied for
- Acute Pain
- Adenocarcinoma
- Anemia
- Anemia, Aplastic
- Colitis
- Colitis, Ulcerative
- Disease
- Hepatitis
- Hepatitis A
- Hepatitis C
- Hodgkin Disease
- Leukemia
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
- Lymphoma
- Lymphoma, Non-Hodgkin
- Mood Disorders
- Multiple Myeloma
- Myelodysplastic Syndromes
- Myeloproliferative Disorders
- Neoplasms, Plasma Cell
- Pancreatic Neoplasms
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Preleukemia
- Psychotic Disorders
- Schizophrenia
- Syndrome
- Ulcer
Marketed drugs (1)
Subsidiaries (1 direct, 1 total across the full acquisition tree)
Recent trials (31)
- NCT06442761CollaboratorPhase 1Dec 31, 2024
- NCT06547112CollaboratorPhase 1Oct 31, 2024
- NCT05618301CollaboratorPhase 1Mar 31, 2023
- NCT04543071CollaboratorPhase 2Aug 30, 2021
- NCT05293171Lead sponsorPhase 1Jun 11, 2021
- NCT03246529Lead sponsorPhase 3Jan 18, 2018
- NCT03154827Lead sponsorPhase 1/Phase 2Sep 17, 2017
- NCT02907099CollaboratorPhase 2Dec 1, 2016
- NCT02826486Study chairPhase 2Sep 1, 2016
- NCT02826486Lead sponsorPhase 2Sep 1, 2016
- NCT02639559CollaboratorPhase 2Mar 31, 2016
- NCT02462252Lead sponsorPhase 2Oct 1, 2015
- NCT02502968CollaboratorPhase 2Sep 1, 2015
- NCT02073019Study chairPhase 1Aug 1, 2014
- NCT02073019Lead sponsorPhase 1Aug 1, 2014
Details
- Founded
- Tel Aviv, IL Jun 1, 2003
- First NDA
- Sep 8, 2023
- Last known activity
- Dec 31, 2024
Designations held
- Orphan drug